Vistagen Therapeutics Inc (VTGN)
4.70
-0.12
(-2.49%)
USD |
NASDAQ |
Apr 24, 15:19
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 127.02M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 11.42% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 60.84 |
| Price to Book Value | 1.030 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.38% |
Profile
| Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. |
| URL | https://www.vistagen.com |
| Investor Relations URL | https://www.vistagen.com/investors/overview |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 28, 2024 (est.) |
| Last Earnings Release | Feb. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. |
| URL | https://www.vistagen.com |
| Investor Relations URL | https://www.vistagen.com/investors/overview |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 28, 2024 (est.) |
| Last Earnings Release | Feb. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |